Moderna President Stephen Hoge said Wednesday that the omicron vaccine booster shot will be ready for U.S. authorization close to March 2022.
- The vaccine would carry “genes specifically targeting mutations in the newly discovered Omicron variant,” according to Reuters.
- Hoge said this would be the quickest way to stop vaccine efficacy from waning.
Stéphane Bancel, the Moderna CEO, recently predicted that the current COVID-19 vaccines will be less effective against omicron, which will require vaccine developers to create a new vaccine, per The Financial Times.
- “There is no world, I think, where (the effectiveness) is the same level ... we had with (the) Delta (variant),” Bancel told the Financial Times.